Ferrocene incorporated selenoureas as anticancer agents.

Area of Science:

• Medicinal Chemistry
• Cancer Research
• Drug Discovery

Background:

• Chemopreventive agents ideally target multiple stages of carcinogenesis: initiation, propagation, and tumor growth.
• Current chemotherapy faces challenges that could be mitigated by agents active across all cancer development stages.
• Cancer initiation involves free radicals and phase I enzymes; propagation is modulated by phase II enzymes; termination requires cytotoxic action.

Purpose of the Study:

• To comprehensively evaluate seventeen ferrocene-incorporated selenoureas as potential chemopreventive agents.
• To assess their efficacy in DNA binding, antioxidant, anti-inflammatory, phase I enzyme inhibition, phase II enzyme induction, and cytotoxic activities.
• To compare their activity profiles against neuroblastoma, liver, and breast cancer cell lines.

Main Methods:

• DNA binding was studied using cyclic voltammetry, UV-vis spectroscopy, and viscometry.
• Antioxidant activity was assessed via DPPH scavenging assays.
• Anti-inflammatory, phase I enzyme inhibition (aromatase), and phase II enzyme induction (quinone reductase) were evaluated.
• Cytotoxic effects were determined against neuroblastoma (MYCN2, SK-N-SH), liver cancer (Hepa 1c1c7), and breast cancer (MCF-7) cell lines.

Main Results:

• The study comprehensively reports comparative DNA binding, antioxidant, anti-inflammatory, phase I enzyme inhibition, phase II enzyme induction, and cytotoxic activities.
• Detailed findings on the seventeen ferrocene-incorporated selenoureas' interactions and biological effects are presented.
• Specific activities and potencies against different cancer cell lines were observed for the tested compounds.

Conclusions:

• Ferrocene-incorporated selenoureas demonstrate multifaceted chemopreventive potential.
• These compounds exhibit promising DNA binding, antioxidant, anti-inflammatory, and cytotoxic properties.
• The findings support further development of these selenoureas as novel anti-cancer agents targeting multiple stages of carcinogenesis.